Results 91 to 100 of about 3,015 (189)

Risk of Neurodegeneration in Patients with Rapid Eye Movement Sleep Behavior Disorder

Journal of Parkinson’s Disease, 2022
I discussed the risk of phenoconversions from idiopathic/isolated REM sleep behavior disorder (iRBD). Comorbidity with iRBD, such as obstructive sleep apnea, may accerelate the risk of α-synuclein-related neurodegenerative diseases.
Tomoyuki Kawada
doaj   +1 more source

Relationship of Mediterranean Diet and Caloric Intake to Phenoconversion in Huntington Disease [PDF]

JAMA Neurology, 2013
Adherence to Mediterranean-type diet (MeDi) may delay onset of Alzheimer and Parkinson diseases. Whether adherence to MeDi affects time to phenoconversion in Huntington disease (HD), a highly penetrant, single-gene disorder, is unknown.To determine if MeDi modifies the time to clinical onset of HD (phenoconversion) in premanifest carriers participating
Marder, Karen, Gu, Yian, Eberly, Shirley, Tanner, Caroline M, Scarmeas, Nikolaos, Oakes, David, Shoulson, Ira   +6 more
openaire   +5 more sources

Generalized EEG Slowing Across Phasic REM Sleep, Not Subjective RBD Severity, Predicts Neurodegeneration in Idiopathic RBD

Nature and Science of Sleep, 2022
Si-Yi Gong,1,* Yun Shen,1,* Han-Ying Gu,1 Sheng Zhuang,1 Xiang Fu,1,2 Qiao-Jun Wang,1 Cheng-Jie Mao,1 Hua Hu,1 Yong-Ping Dai,1 Chun-Feng Liu1– 3 1Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated ...
Gong SY, Shen Y, Gu HY, Zhuang S, Fu X, Wang QJ, Mao CJ, Hu H, Dai YP, Liu CF   +9 more
doaj  

Uncoupling TGFβ1 signalling from collagen protein synthesis in Dupuytren's disease

The Journal of Pathology, Volume 268, Issue 4, Page 383-397, April 2026.
Abstract Dupuytren's disease is a fibroproliferative disorder of the palmer fascia (PF) characterised by flexion contractures in the hand. Dupuytren's disease can be treated surgically, but disease recurrence rates are high, potentially due to continual production of matrisomal proteins.
Gabriella Cooper, Jade A Gumbs, Sahem Alkharabsheh, Katie J Lee, Alan Carter, Hannah Coleman, Niamh S O'Heneghan‐Yates, Rama Ijaz, Emma Beamish, Lisa A Menezes, Triantafillos Liloglou, Peter D Clegg, Elizabeth G. Canty‐Laird   +12 more
wiley   +1 more source

Synuclein Disorder‐Related Genetic Determinants of Mild Behavioural Impairment in a Pre‐Clinical Community Cohort

International Journal of Geriatric Psychiatry, Volume 41, Issue 3, March 2026.
ABSTRACT Background The GBA variant confers increased risk of synuclein disorders but it is unclear what impact it has in pre‐clinical groups. This study aimed to identify early psychiatric and cognitive manifestations amongst pre‐clinical GBA carriers in a community cohort.
Millie Sander‐Long, Byron Creese, Anne Corbett, Ivana Rosenzweig, Jeffrey Cummings, Clive Ballard   +5 more
wiley   +1 more source

Defining pre-symptomatic amyotrophic lateral sclerosis [PDF]

, 2019
Successful treatment of neurodegenerative disease may hinge on early therapeutic intervention. This requires an understanding of early/pre-symptomatic disease, a need that is underscored by advances in antisense oligonucleotide, and viral-vector-based ...
Benatar, M, Turner, Martin, Wuu, J
core   +2 more sources

Clinician Satisfaction With Pharmacogenomics Clinical Services at a Multistate Health System

Clinical and Translational Science, Volume 19, Issue 3, March 2026.
ABSTRACT Pharmacogenomics (PGx) utilizes genetic information to optimize medication management. Barriers to PGx implementation include limited confidence and knowledge in applying results, time constraints, and financial barriers. Clinical services across health systems vary greatly with differing consultative PGx service models.
Kristen Jacobsen, Natasha J. Petry, Max Weaver, Ethan Weeder, Amanda Massmann   +4 more
wiley   +1 more source

Clinical effects of CYP2D6 phenoconversion in patients with psychosis

Journal of Psychopharmacology
Background: Pharmacogenetics is considered a promising avenue for improving treatment outcomes, yet evidence arguing for the use of pharmacogenetics in the treatment of psychotic disorders is mixed and clinical usefulness is under debate.
Emma Y De Brabander, Esmee Breddels, Therese van Amelsvoort, Roos van Westrhenen   +3 more
openaire   +3 more sources

Longitudinal evolution of cortical thickness signature reflecting Lewy body dementia in isolated REM sleep behavior disorder: a prospective cohort study

Translational Neurodegeneration, 2023
Background The isolated rapid-eye-movement sleep behavior disorder (iRBD) is a prodromal condition of Lewy body disease including Parkinson's disease and dementia with Lewy bodies (DLB).
Jung Hwan Shin, Heejung Kim, Yu Kyeong Kim, Eun Jin Yoon, Hyunwoo Nam, Beomseok Jeon, Jee-Young Lee   +6 more
doaj   +1 more source

Impact of CYP2D6 Metabolizer Status on Ondansetron Efficacy in Early Pregnancy Induced Nausea and Vomiting: A Case Control Study

Clinical and Translational Science, Volume 19, Issue 3, March 2026.
ABSTRACT Real‐world data investigating CYP2D6 on the efficacy of ondansetron for nausea and vomiting in pregnancy (NVP) is lacking. Evidence shows CYP2D6 ultrarapid metabolizers are at risk of ondansetron nonresponse due to increased metabolism. We conducted a retrospective cohort study of early pregnant patients on ondansetron for NVP.
Michelle Liu, Megan M. Shuey, Sabrina E. Holley, Darlene F. Fountain, James Jaworski, Carol Griffin, Jeewoo Kim, Melissa Stec, Sudeep D. Sunthankar, Henry H. Ong, Srushti Gangireddy, Wei‐Qi Wei, Andrea Gaedigk, Digna R. Velez Edwards, Vivian K. Kawai   +14 more
wiley   +1 more source